Next-Generation QACs.
Powerful Against Pathogens.
Engineered to Biodegrade.
Embedded Files
The Mission
Science-led. Evidence-driven. Impact-focused.
Science-led. Evidence-driven. Impact-focused.
We are developing novel, patent-protected olefinic quaternary ammonium compounds (OQA compounds) - the next generation of QACs that deliver broad-spectrum antimicrobial efficacy with reduced environmental persistence.
Traditional QACs like BAC and DDAC are highly effective but slow to degrade in the environment. Our OQA compounds maintain antimicrobial potency while being engineered for enzymatic degradation, addressing both infection prevention and environmental sustainability.
The Team
The Team
Dr Alan Cameron
Dr Alan Cameron
Co-Founder | Chemistry
A specialist in organic and medicinal chemistry, Alan is a co-inventor of our technology and leads the scientific development of OleQuat’s next-generation QAC platform. His research background bridges synthetic chemistry and practical formulation design, with a focus on creating safer, more effective compounds.
Dr Kristi Biswas
Dr Kristi Biswas
Co-Founder | Microbiology
Kristi is a microbiologist with deep expertise in bacterial biofilms and infection dynamics. She drives OleQuat’s biological validation and testing programmes. Her work underpins the scientific evidence for B3a’s performance in a range of applications.
Craig Squire
Craig Squire
Co-Founder | Commercial and CEO
Craig brings a decade of experience investing in and working with start-up ventures and compex technlogies in New Zealand. At OleQuat he oversees commercial strategy, partnerships, and capital development, connecting world-class science with real-world impact across multiple sectors.
Contact Us
We are actively engaging with strategic partners. If you are interested, please contact us. We would love to hear from you.
info@olequat.com
Page updated
Report abuse